ArticleBMC endocrine disorders2026
MTHFR variants modify the association between pre-pregnancy BMI and postpartum abnormal glucose tolerance among women with gestational diabetes mellitus.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMethylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and obesity are associated with glucose metabolism dysregulation. This study aimed to investigate the individual and joint effects of MTHFR gene polymorphisms and pre-pregnancy body mass index (pre-BMI) status on postpartum abnormal glucose tolerance (PAGT) risk among women with gestational diabetes mellitus (GDM).
methodsThis retrospective study enrolled 1181 women with GDM who underwent a postpartum oral glucose tolerance testing for 6-12 weeks in Guangzhou, China. The association between MTHFR gene polymorphism and pre-BMI status with PAGT risk was assessed using logistic regression models, followed by stratified analyses.
resultsAmong the included women with GDM, the overall prevalence of PAGT was 28.96%, and the prevalence of pre-pregnancy obesity was 4.23%. Pre-pregnancy obesity and carriage of the MTHFR A1298C AC + CC genotype were independently associated with a significantly elevated risk of PAGT. Stratified analyses by MTHFR variants dominant models revealed that women with obesity carrying the MTHFR C677T CT + TT genotype had an elevated risk of PAGT (odds ratio [OR] = 3.99, 95% confidence interval [CI]: 1.21-13.18). Among A1298C AA genotype carriers, pre-pregnancy obesity was associated with a 4.85-fold higher risk of PAGT (95% CI 1.35-17.41), whereas pre-pregnancy underweight correlated with a significantly reduced PAGT risk (OR = 0.37, 95% CI 0.14-0.99). Furthermore, in the normal weight subgroup, women harboring the MTHFR A1298C AA genotype combined with the C677T CT + TT genotype had a significantly decreased risk of PAGT (OR = 0.59, 95% CI 0.35-0.98), compared with those carrying the MTHFR A1298C AC + CC genotype combined with the C677T CT genotype.
conclusionPre-pregnancy obesity is an independent risk factor for PAGT in women with GDM, and this association could be modified by MTHFR gene polymorphisms. Further large-scale prospective studies are warranted to evaluate whether genotype-guided folic acid supplementation can reduce PAGT risk in high-risk women with GDM, particularly those with pre-pregnancy obesity. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.